Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Authors: Currie, Craig J.1; McEwan, Phil2; Poole, Chris3; Valentine, William J.4; Palmer, Andrew J.4; Lammert, Morten5; Nicklasson, Lars6; Foos, Volker4; Roze, Stéphane4

Source: Current Medical Research and Opinion, Volume 22, Number 5, May 2006 , pp. 967-969(3)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Document Type: Letter section

DOI: 10.1185/030079906X00000

Affiliations: 1: Honorary Senior Research Fellow, Diabetes, Endocrinology and Metabolism, School of Medicine, Cardiff University, UK 2: Lecturer in Computational Statistics, School of Mathematics, Cardiff University, UK 3: Senior Research Pharmacist, Cardiff, UK 4: ORE – Center for Outcomes Research, Bündtenmattstrasse 40, 4102 Binningen, Switzerland 5: Novo Nordisk A/S, Bagsvaerd, Denmark 6: Novo Nordisk Inc., Princeton, NJ, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A